BLSM logo

BlossomHill Therapeutics, Inc.

BLSM
Healthcare|Biotechnology|US
$13.50
+1.15 (+9.31%)
DCF Value
$3.85
Tangible Book / Share
$3.02
Cash / Share
$3.51
Next Earnings Report
Dec 18, 2026
EPS est. -$0.93
Financing Filings (last 12 months)
4
Shelf registrations / offering prospectuses — latest Aug 7, 2026 (424B4). Possible dilution.

Upcoming Data Readouts (1)

Jan 2029
Est. completion
P1P2NSCLC (Advanced Non-small Cell Lung Cancer)
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
NCT06706076n=675

Recent Press Releases

BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual Meeting
Nov 4, 2026 · GlobeNewsWire
BlossomHill Therapeutics to Present at Guggenheim's 3rd Annual Healthcare Innovations Conference
Nov 3, 2026 · GlobeNewsWire
BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer
Oct 22, 2026 · GlobeNewsWire
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
Sep 28, 2026 · GlobeNewsWire
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
Sep 18, 2026 · GlobeNewsWire
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
Sep 15, 2026 · GlobeNewsWire
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference
Sep 3, 2026 · GlobeNewsWire
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
Sep 1, 2026 · GlobeNewsWire
BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC
Aug 18, 2026 · GlobeNewsWire

SEC Filings (19)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Sep 18, 202610-QQuarterly reportDocumentIndex
Sep 18, 20268-KMaterial eventDocumentIndex
Sep 15, 20268-KMaterial eventDocumentIndex
Aug 18, 2026SC 13DActivist / 5%+ stakeDocumentIndex
Aug 17, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 14, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 13, 2026SC 13DActivist / 5%+ stakeDocumentIndex
Aug 10, 2026S-8Employee stock planDocumentIndex
Aug 10, 20268-KMaterial eventDocumentIndex
Aug 7, 2026424B4Offering prospectusDocumentIndex
Aug 6, 2026EFFECTDocumentIndex
Aug 6, 2026S-1MEFIPO / offering registrationDocumentIndex
Aug 6, 2026CERTDocumentIndex
Aug 4, 20268-A12BDocumentIndex
Aug 3, 2026S-1/AIPO / offering registrationDocumentIndex
Jul 17, 2026S-1IPO / offering registrationDocumentIndex
Jun 11, 2026DRS/ADocumentIndex
Apr 24, 2026DRSDocumentIndex
Dec 10, 2025DDocumentIndex